ImmunityBio
$10.29Change from previous close: +10.83%Absolute change: +$1.01
At a glance
- Revenue growth
- +668.31%
- 2025 vs 2024
- Net margin
- -310.2%
- 2024: -2,804.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -305 | -391 | -367 | -338 | — |
| Depreciation and amortization | 15.5 | 17.6 | 18.5 | 18.3 | — |
| Capital expenditure | -4.3 | -6.9 | -30.6 | -99.4 | — |
| Investing cash flow | -150 | -12.2 | -30.5 | 27.3 | — |
| Financing cash flow | 400 | 282 | 558 | 234 | — |
| Share repurchases | — | — | — | — | 0.0 |
| Debt issued | 2.9 | 0.0 | 259 | 174 | — |
| Debt repaid | -0.0 | -0.1 | -0.1 | -0.1 | — |
| Effect of exchange rates | 0.0 | -0.0 | -0.3 | 0.3 | — |
| Net change in cash | -54.5 | -122 | 161 | -76.6 | — |
| Free cash flow | -309 | -398 | -397 | -437 | — |